Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Additionally, in vivo assays revealed hsa_circRNA_103809 short hairpin RNA served as a tumor suppressor through downregulating FGFR1 in HCC.
|
31317555 |
2020 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Tumor-associated inflammatory microenvironment in non-small cell lung cancer: correlation with FGFR1 and TLR4 expression via PI3K/Akt pathway.
|
30854106 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, FGFR1 silencing mimicked the tumor‑suppressing roles of miR‑802 upregulation in NSCLC cells.
|
30942425 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, FGFR1 silencing elicited a similar tumor-suppressive effect as miR-198 overexpression.
|
31138759 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In the dose-expansion phase, all patients provided an archival formalin-fixed paraffin-embedded (FFPE) tumour biopsy or consented to a new biopsy at screening for the analysis of FGFR1-3 mRNA expression.
|
31405822 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The 8p11 myeloproliferative syndrome (EMS) is an aggressive neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 (FGFR1) tyrosine kinase gene on chromosome 8p11-12.
|
29614500 |
2019 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to uncover the expression of FGFR1 and FGFR3 proteins in choroid plexus tumors and to further characterize FGFR-related as well as other genetic alterations in FGFR3 expressing tumors.
|
31660579 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
MicroRNA (miRNA) and fibroblast growth factor receptor 1 (FGFR1) dysregulation are considered to play an important role in tumor proliferation, invasion, and metastasis.
|
31492847 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Xenograft experiments confirmed that circRAPGEF5 knockdown suppressed FGFR1-mediated tumor growth by promoting miR-198 expression. circRAPGEF5 acts as a tumor promoter via a novel circRAPGEF5/miR-198/FGFR1 axis, providing a potential biomarker and therapeutic target for the management of PTC.
|
30785065 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This tumor type shares some morphological features with chondroblastoma-like osteosarcoma and we cannot rule out that the present case actually represents an FN1-FGFR1 positive malignant phosphaturic mesenchymal tumor of bone without osteomalacia.
|
31066955 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Xenografts were established with PC9<sup>gFGFR1</sup> cells and it was demonstrated that there was no significant difference in tumor size between TKI- and vehicle-treated PC9<sup>gFGFR1</sup> tumors.
|
30562682 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
However, alterations in FGFRs 1-4, such as amplifications, fusions and mutations, as well as aberrant epigenetic or transcriptional regulation and changes in tumour-stromal interactions in the tumour microenvironment, can lead to the development and/or progression of cancer.
|
30367139 |
2019 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
High FGFR1 expression was associated with age, malignancy, tumor location and tumor grade among astrocytomas.
|
30931252 |
2019 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genetic analysis of this rare tumor identified 3 hotspots involving somatic mutations of FGFR-1 and PIK3CA and a germline mutation involving PTPN11, which can be targets for therapeutic intervention in cases where complete resection is not possible.
|
30790744 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The FGF2/FGFR1 paracrine loop is involved in the cross-talk between breast cancer cells and components of the tumor stroma as cancer-associated fibroblasts (CAFs).
|
30866584 |
2019 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
MicroRNA-133b (miR-133b), through directly targeting the fibroblast growth factor receptor 1 (FGFR1), is increasingly recognized as a tumor suppressor in different types of cancers.
|
30574019 |
2018 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
The level of FGFR1 amplification did not correlate with tumor stage, lymph node staging, or metastasis.
|
29351293 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The immunohistochemical results were as follows: the tumour cells were positive for FGF23 (nine of 12, 75%), FGFR1 (11 of 11, 100%), CD56 (12 of 14, 85.7%) and E26 oncogene homologue (ERG) (5 of 13, 38.4%).
|
28858396 |
2018 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Genetic testing revealed a somatic FN1-FGFR1 translocation in the FGF23-producing tumor causing TIO; however, a germline PTEN mutation was not identified.
|
29380000 |
2018 |
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In discovery cohort 1, FGFR1 and Klotho beta (KLB) overexpression was associated with low tumor stage (P < 0.05), low tumor grade (P < 0.05), and better overall survival.
|
30593273 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results suggest that genomic alterations involving the cell cycle (TP53, CCND1, CDKN2A), as well as FGFR1 amplifications and tumour genomic alterations burden are prognostic biomarkers and might be therapeutic targets for patients with HNSCC.
|
29331751 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This positive association of miR-17/92 with BCR-FGFR1 was also confirmed in primary mouse SCLL tissues and primary human CLL samples. miR-17/92 promotes cell proliferation and survival by targeting CDKN1A and PTEN in B-lymphoma cell lines and primary tumors.
|
29367757 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor FGFR1 phosphorylation was elevated with obesity and predicted a shorter disease-free and disease-specific survival for patients treated with tamoxifen.
|
30046001 |
2018 |
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
He was started on trametinib, a MEK inhibitor, off-label, targeting the MAPK pathway downstream from FGFR1, with stable tumor size at last follow-up, after 6 months on therapy.
|
29683947 |
2018 |
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.
|
29486661 |
2018 |